Evidence check: CYP1A2 in the context of Darmgesundheit

CYP1A2 is an enzyme primarily known for metabolizing caffeine and certain drugs. In the context of gut health, evidence is limited and mostly mechanistic: CYP1A2 may influence the gut microbiome or intestinal barrier through metabolism of dietary compounds (e.g., polyphenols) or toxins. Some studies suggest a link between CYP1A2 activity and inflammatory bowel disease, but effects are small and inconsistent. The evidence is predominantly mechanistic, from in vitro or animal studies. Direct human studies on gut health are lacking. Therefore, a DNA test for CYP1A2 variants (e.g., rs762551) cannot reliably indicate individual gut health. Interpretation remains speculative and should not guide dietary or supplement choices. Beware of overblown marketing claims.